Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women

被引:18
|
作者
Nowicki, MJ
Laskus, T
Nikolopoulou, G
Radkowski, M
Wilkinson, J
Du, WBB
Rakela, J
Kovacs, A
机构
[1] Univ So Calif, Dept Pediat, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA
[2] Mayo Clin, Scottsdale, AZ USA
[3] Med Acad, Warsaw, Poland
[4] St Josephs Hosp, Phoenix, AZ USA
来源
JOURNAL OF INFECTIOUS DISEASES | 2005年 / 192卷 / 09期
关键词
D O I
10.1086/491742
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hepatitis C virus (HCV) - infected women - in particular, those coinfected with human immunodeficiency virus type 1 (HIV-1) - can transmit infection to their children and sex partners. Methods. The present study was conducted to analyze the presence of HCV RNA in cervicovaginal lavage (CVL) fluid from 71 women (58 HCV/HIV- 1 - coinfected women and 13 HCV-infected, HIV-1-uninfected women) enrolled in the Women's Interagency HIV Study. Results. HCV RNA was detected ( by a commercial polymerase chain reaction assay) in CVL fluid from 18 (29%) of the HIV-1 -infected women and from none of the HIV-1-uninfected women (P < .05). Multivariate analysis revealed that risk factors for the presence of HCV RNA in CVL fluid were HCV viremia ( odds ratio [OR], 16.81; P = .02) and HIV- 1 RNA in CVL fluid ( OR, 19.87; P = .02). This observation suggests local interactions between HIV- 1 and HCV in the genital tract compartment. There was no correlation between HCV RNA in CVL fluid and CD4, CD8, or CD3 cell counts, HIV- 1 RNA viremia, the number of leukocytes in CVL fluid, or HIV- 1 therapy. Furthermore, in 3 of 5 analyzed patients who had a detectable CVL HCV RNA load, we found viral variants differing in the 5' untranslated region that were present neither in plasma nor in peripheral-blood mononuclear cells. Conclusions. Our observations point to the importance of the genital tract compartment, in which local HCV replication could be facilitated by local HIV- 1 replication.
引用
收藏
页码:1557 / 1565
页数:9
相关论文
共 50 条
  • [21] Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
    Trimoulet, P.
    Belzunce, C.
    Faure, M.
    Wittkop, L.
    Reigadas, S.
    Dupon, M.
    Ragnaud, J-M
    Fleury, H.
    Neau, D.
    HIV MEDICINE, 2011, 12 (08) : 506 - 509
  • [22] Time Requirements for Acquisition of Hepatitis C Virus Therapy in HIV/HCV Coinfected Patients
    McLaughlin, Milena
    Kalfayan, Niree
    Grant, Jennifer
    Hawkins, Claudia
    Cottreau, Jessica
    Palella, Frank J., Jr.
    Stosor, Valentina
    JOURNAL OF PHARMACY TECHNOLOGY, 2018, 34 (04) : 149 - 152
  • [23] Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects
    Butt, A. A.
    Justice, A. C.
    Skanderson, M.
    Good, C.
    Kwoh, C. K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) : 585 - 591
  • [24] Chronic hepatitis C in HIV-HCV coinfected patients
    Gervais, A
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2002, 26 : B121 - B132
  • [25] Interferon therapy in patients coinfected with hepatitis C (HCV) and human immunodeficiency virus (HIV).
    Venkataramani, A
    Rond, R
    Beaumont, C
    Lyche, K
    HEPATOLOGY, 1997, 26 (04) : 738 - 738
  • [26] European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients
    Guzman-Fulgencio, M.
    Rallon, N.
    Berenguer, J.
    Fernandez-Rodriguez, A.
    Soriano, V.
    Miralles, P.
    Jimenez-Sousa, M. A.
    Restrepo, C.
    Lopez, J. C.
    Garcia-Alvarez, M.
    Aldamiz, T.
    Benito, J. M.
    Resino, S.
    HIV MEDICINE, 2014, 15 (07) : 425 - 430
  • [27] Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients
    Cesari, M.
    Caramma, I.
    Antinori, S.
    Adorni, F.
    Galli, M.
    Milazzo, L.
    HIV MEDICINE, 2009, 10 (09) : 580 - 585
  • [28] Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV-HCV-coinfected patients
    Piroth, L
    Bourgeois, C
    Dantin, S
    Waldner, A
    Grappin, M
    Portier, H
    Chavanet, P
    AIDS, 1999, 13 (04) : 523 - 524
  • [29] Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy
    Blackard, JT
    Yang, YJ
    Bordoni, P
    Sherman, KE
    Chung, RT
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (08): : 1472 - 1481
  • [30] Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease
    Yoo, TW
    Donfield, S
    Lail, A
    Lynn, HS
    Daar, ES
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (01): : 4 - 10